/ /

The Takeaway Podcast

How to recognize sinus tracts, keratinous cystsIn part three of the discussion on isotretinoin, our experts discuss distinguishing sinus tracts or keratinous cysts from nodular areas of inflammation and techniques for treating via intralesional injection.
Isotretinoin dosing decisionsDermatology Times editorial advisor, Dr. Elaine Siegfried continues the discussion on isotretinoin with James Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania. Here, the two discuss isotretinoin dosing and side effects.
Isotretinoin's discovery and development seriesDr. Jim Leyden, an active participant in isotretinoin's drug development process, discusses many of the important initial clinical observations and those that others have made over the years.
Isotretinoin’s discovery and developmentDermatology Times editorial advisor Dr. Elaine Siegfried talks with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania about the art and science of isotretinoin therapy. Dr. Leyden, aside from being a member of the famed Acne Mafia, was a really active participant in the drug development process for isotretinoin, a drug for which, the institutional memory about that process may be fading. The two discuss many of the important initial clinical observations and those that others have made over the years.
Screening labs, complacency, and the ABCDEs of pediatric melanomaIn part three of our discussion about pediatric dermatology, Kelly Cordoro, M.D., associate professor of dermatology and pediatrics at the University of California in San Francisco, discusses screening labs, avoiding complacency, and the ABCDEs of melanoma with Dermatology Times editorial advisor, Elaine Siegfried, M.D.
Pediatric psoriasis, eczema: Triggers and therapiesIn part two of our discussion, Kelly Cordoro, M.D., associate professor of dermatology and pediatrics at the University of California in San Francisco, discusses environmental and microbial triggers and when to choose systemic therapies with Dermatology Times editorial advisor, Elaine Siegfried, M.D.
Clinical pearls in pediatric dermatologyPediatric dermatology is a rewarding area of special interest for dermatologists. Overlapping conditions, the need for extra-gentle skin care, patient compliance, and medication adherence all present unique challenges for pediatric dermatologists. In part one of our discussion, Kelly Cordoro, M.D., associate professor of dermatology and pediatrics at the University of California in San Francisco, discusses differentiating diseases and treatment recommendations with Dermatology Times editorial advisor, Elaine Siegfried, M.D.
Sunscreen safety and efficacy
Sunscreen safety and efficacySunscreens have become a staple tool in our fight against skin cancer. In spite of the great progress made in educating the public about the value of sunscreens, there remain many doubters about the safety and efficacy of these chemicals. Darrell Rigel, M.D., clinical professor of dermatology at New York University, will help to set the record straight on these agents.
PODCAST: Expert insights in managing vitiligo, part 2 on dyspigmentationTwo of the most vexing skin conditions that dermatologists manage are melasma and vitiligo. In one condition, too much pigmentation is present because of genetic, hormonal and environmental factors. In the other, there is a lack of melanin in the skin, presumably on an autoimmune basis. In part two of this discussion on dyspigmentation conditions, Seemal Desai, M.D., who is a board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options for vitiligo with Dermatology Times editorial advisor, Dr. Norman Levine.
PODCAST: Expert insights in managing melasma, part 1 on dyspigmentationTwo of the most vexing skin conditions that dermatologists manage are melasma and vitiligo. In one condition, too much pigmentation is present because of genetic, hormonal and environmental factors. In the other, there is a lack of melanin in the skin, presumably on an autoimmune basis. In part one of this discussion on dyspigmentation conditions, Seemal Desai, M.D., who is a board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options for melasma Dermatology Times editorial advisor, Dr. Norman Levine.